Hod Moshe, Damm Peter, Kaaja Risto, Visser Gerard H A, Dunne Fidelma, Demidova Irina, Hansen Anne-Sofie Pade, Mersebach Henriette
Perinatal Division, Helen Schneider Hospital for Women, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Petah-Tiqva, Israel.
Am J Obstet Gynecol. 2008 Feb;198(2):186.e1-7. doi: 10.1016/j.ajog.2007.08.005. Epub 2007 Oct 1.
The objective of the study was a comparison of insulin aspart (IAsp) with human insulin (HI) in basal-bolus therapy with neutral protamine Hagedorn for fetal and perinatal outcomes of type 1 diabetes in pregnancy.
This was a randomized, parallel, open-label, controlled, multicenter, multinational study. Subjects were pregnant (gestational age; <10 weeks) or planning pregnancy at enrollment. Three hundred twenty-two women with type 1 diabetes received IAsp (n = 157) or HI (n = 165).
For IAsp and HI, respectively, there were 137 and 131 live births and 14 and 21 fetal losses. Perinatal mortality was 14 and 22 per 1000 births; number of congenital malformations were 6 and 9; mean (SEM) birthweight corrected for gestational age was 3438 g (71.5) and 3555 g (72.9; P = .091). Mean gestational age was 37.6 vs 37.4 weeks. Preterm delivery occurred in 20.3% (IAsp) and 30.6% (HI) of pregnancies (P = .053).
The fetal outcome using IAsp was comparable with HI with a tendency toward fewer fetal losses and preterm deliveries.
本研究的目的是比较门冬胰岛素(IAsp)与重组人胰岛素(HI)在基础-餐时疗法联合中效低精蛋白胰岛素治疗中对妊娠1型糖尿病胎儿及围产期结局的影响。
这是一项随机、平行、开放标签、对照、多中心、跨国研究。受试者在入组时已怀孕(孕周<10周)或计划怀孕。322例1型糖尿病女性接受了IAsp(n = 157)或HI(n = 165)治疗。
IAsp组和HI组分别有137例和131例活产,14例和21例胎儿丢失。围产儿死亡率分别为每1000例出生中有14例和22例;先天性畸形数分别为6例和9例;校正孕周后的平均(SEM)出生体重分别为3438 g(71.5)和3555 g(72.9;P = 0.091)。平均孕周分别为37.6周和37.4周。20.3%(IAsp组)和30.6%(HI组)的妊娠发生早产(P = 0.053)。
使用IAsp的胎儿结局与HI相当,胎儿丢失和早产有减少趋势。